
|Articles|February 26, 2007
Helixate FS, Mix2Vial now packaged together
Advertisement
CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Shows Improvements in Blood Sugar, Cardiovascular Risk Factors
2
Q&A: Fentanyl, Opiophobia Concurrently Contribute to Ongoing Opioid Crisis
3
Finerenone Shows Benefits for Chronic Kidney Disease for Patients With Type 1 Diabetes
4




















































































































































